Pulmonary Arterial Hypertension Market Offers Opportunity for New and Established Agents

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• An Attractive Target
• Overview of PAH
• Disease Characteristics, Diagnosis, and Prevalent Cases
• Risk Factors, Disease Pathways, and Drug Targets
• Approved Drug Therapies
• Flolan
• Tracleer
• Revatio
• Remodulin
• Ventavis
• Other Drug Therapies
• Combination Therapy
• Promising New Therapies
• Novel Endothelin Receptor Antagonists: Ambrisentan vs Thelin
• Reformulated Prostacyclin Analogues: Inhaled and Oral Remodulin
• PDE-5 Inhibitors: Cialis, Levitra, and UK-369003
• Vasoactive Intestinal Peptide Derivatives: Aviptadil
• Serotonin Pathway Antagonists: PRX-08066 and Cipralex/Lexapro
• Tyrosine Kinase Inhibitors: Gleevec
• Other Promising Pipeline Agents
• Outlook
• Market Drivers and Constraints
• Pulmonary Arterial Hypertension Market Through 2010

Tables

• 1. Prevalence of Pulmonary Arterial Hypertension, 2005
• 2. Molecular Targets for Current and Future PAH Therapies
• 3. Major Marketed Drugs for PAH
• 4. Emerging Therapies for the Treatment of Pulmonary Hypertension
• 5. Approval Status of Current PAH Therapies
• 6. Forecast of Regional Sales of Major PAH Drug Classes, 2010

Figures

• 1. Classifications of Pulmonary Arterial Hypertension
• 2. Risk Factors for Pulmonary Arterial Hypertension
• 3. Market Share of Current PAH Therapies in the Seven Major Markets, 2005